Bank of America
AUPH icon

Bank of America’s Aurinia Pharmaceuticals AUPH Stock Holding History

Bank of America’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7,000
Closed -$160K – 8246
2021
Q4 		$160K Buy
+7,000
New +$166K ﹤0.01% 6621
2020
Q1 		– Sell
-42,000
Closed -$851K – 6830
2019
Q4 		$851K Buy
+42,000
New +$387K ﹤0.01% 4615

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of America's AUPH Position: Q1 2026 in Review

Bank of America increased its Aurinia Pharmaceuticals (AUPH) stake by 1.1% in Q1 2026, buying an estimated $60.6K and bringing the position to 371,781 shares worth $5.51M. The position accounts for ﹤0.01% of the portfolio, ranked #3391.

Bank of America first reported a position in AUPH in Q2 2015 and has held it in 40 quarters since. The position peaked at $5.86M in Q4 2025. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

  • Bank of America held 371,781 shares of Aurinia Pharmaceuticals worth $5.51M as of Q1 2026.
  • Bank of America bought 4,145 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $60.6K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3391 holding.
  • Bank of America first reported a position in Aurinia Pharmaceuticals in Q2 2015 and has held it in 40 quarters since.
  • Bank of America's Aurinia Pharmaceuticals position peaked at $5.86M in Q4 2025.
  • 259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.